Chromomycin A3 for advanced breast cancer: a Southwest Oncology Group study
Samal, B.; Jones, S.; Brownlee, R.W.; Morrison, F.; Hoogstraten, B.; Caoili, E.; Baker, L.
Cancer Treatment Reports 62(1): 19-22
1978
ISSN/ISBN: 0361-5960 PMID: 342093 Document Number: 134963
Chromomycin A3 was administered iv to 26 patients in a phase I trial. The maximum tolerated dose established in this study was 0.75 mg/m2/day iv X 5 days. The drug was then given to 48 evaluable patients with far-advanced disseminated breast cancer. Two short partial remissions and one clinical improvement were seen. Toxic manifestations consisted of frequent and usually reversible renal toxicity, nausea and vomiting, occasional thrombocytopenia, hypocalcemia, and two instances of semicoma. Drug toxicity may have contributed to the death of two patients.
Document emailed within 1 workday
Related Documents
Goodwin, W.; Stephens, R.; McCracken, J.D.; Groppe, C. 1981: Therapy for advanced colorectal cancer with a combination of 5-FU and anguidine: a Southwest Oncology Group Study Cancer Treatment Reports 65(3-4): 359Gagliano, R.G.; Panettiere, F.J.; Haas, C.D.; Baker, L.; Hewlett, J.; Stuckey, W.J.; O'Bryan, R.M.; Bottomley, R.; Heilburn, L.K. 1981: Evaluation of beta-2'-deoxythioguanosine combined with methyl-CCNU or mitomycin in advanced colorectal cancer. a Southwest Oncology Group study Cancer Clinical Trials 4(4): 401-405
Knight, W.A.; Loesch, D.M.; Leichman, L.P.; Fabian, C.; O'Bryan, R.M. 1982: Methyl-GAG in advanced colon cancer: a phase Ii trial of the Southwest Oncology Group Cancer Treatment Reports 66(12): 2099-2100
Goldberg, R.M.; Fleming, T.R.; Tangen, C.M.; Moertel, C.G.; Macdonald, J.S.; Haller, D.G.; Laurie, J.A. 1998: Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group Annals of Internal Medicine 129(1): 27-35
Levin, M.; Pandya, K.J.; Khandekar, J.D.; Horton, J.; Glick, J.H.; Bennett, J.M.; Muggia, F.M.; Falkson, G. 1984: Phase Ii study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot study Cancer Treatment Reports 68(12): 1511-1512
Saiki, J.H.; Baker, L.H.; Stephens, R.L.; Fabian, C.J.; Kraut, E.H.; Fletcher, W.S. 1982: Gallium nitrate in advanced soft tissue and bone sarcomas: a Southwest Oncology Group Study Cancer Treatment Reports 66(8): 1673-1674
Taylor, S.A.; Von Hoff, D.D.; Baker, L.H.; Balcerzak, S.P. 1984: Phase Ii clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study Cancer Treatment Reports 68(6): 919-920
Miller, T.P.; Jones, S.E.; Rainey, J.M. 1983: Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with advanced Hodgkin's disease: a Southwest Oncology Group Phase Ii Study Cancer Treatment Reports 67(7-8): 739-740
Oishi, N.; Berenberg, J.; Blumenstein, B.A.; Johnson, K.; Rivkin, S.E.; Bukowski, R.M.; O'Bryan, R.M.; Stephens, R.L.; Quagliana, J.; Saiers, J.H. 1987: Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study Cancer Treatment Reports 71(12): 1307-1308
Ahnen, D.J.; Feigl, P.; Quan, G.; Fenoglio-Preiser, C.; Lovato, L.C.; Bunn, P.A.; Stemmerman, G.; Wells, J.D.; Macdonald, J.S.; Meyskens, F.L. 1998: Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study Cancer Research 58(6): 1149-1158
Weiss, G.B.; Metch, B.; Von Hoff, D.D.; Taylor, S.A.; Saiers, J.H. 1987: Phase Ii trial of fludarabine phosphate in patients with head and neck cancer: a Southwest Oncology Group Study Cancer Treatment Reports 71(12): 1313-1314
Sledge, G.W.; Robert, N.; Sparano, J.A.; Cogleigh, M.; Goldstein, L.J.; Neuberg, D.; Rowinsky, E.; Baughman, C.; McCaskill-Stevens, W. 1995: Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer Seminars in Oncology 22(3 Suppl 6: 105-108
Leichman, L.; Steiger, Z.; Seydel, H.G.; Vaitkevicius, V.K. 1984: Combined preoperative chemotherapy and radiation therapy for cancer of the esophagus: the Wayne State University, Southwest Oncology group and Radiation Therapy Oncology Group experience Seminars in Oncology 11(2): 178-185
Sledge, G.W.; Robert, N.; Sparano, J.A.; Cobeligh, M.; Goldstein, L.J.; Neuberg, D.; Rowinsky, E.; Baughman, C.; McCaskill-Stevens, W. 1994: Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience Seminars in Oncology 21(5 Suppl 8: 15-18
Taguchi, T.; Koyama, H.; Yayoi, K.; Wada, T.; Takatsuka, Y.; Sonoo, H.; Morimoto, K.; Tominaga, T.; Abe, R.; Enomoto, K. 1995: Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(4): 495-508
Hilgers, R.D.; Von Hoff, D.D.; Stephens, R.L.; Boutselis, J.G.; Rivkin, S.E. 1985: Mitoxantrone in adenocarcinoma of the endometrium: a Southwest Oncology Group Study Cancer Treatment Reports 69(11): 1329-1330
Tominaga, T.; Nomura, Y.; Adachi, I.; Aoyama, H.; Nagao, K.; Mitsuyama, S.; Nakamura, Y.; Ogita, M.; Sano, M.; Takashima, S. 1994: Late phase II study of KW-2307 in advanced or recurrent breast cancer. KW-2307 Cooperative Study Group (Breast Cancer Section) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(6): 809-816
Thigpen, J.T.; Al-Sarraf, M.; Hewlett, J.S. 1979: Phase Ii trial of dianhydrogalactitol in metastatic malignant melanoma: a Southwest Oncology Group study Cancer Treatment Reports 63(4): 525-528
Ratanatharathorn, V.; Gad-el-Mawla, N.; Wilson, H.E.; Bonnet, J.D.; Rivkin, S.E.; Mass, R. 1982: Phase II evaluation of maytansine in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group study Cancer Treatment Reports 66(7): 1687-1688
Lawson, D.; Moore, M.; Smalley, R. 1980: An evaluation of hexamethylmelamine, cis-diamminedichloroplatinum, and mitomycin-C in advanced breast cancer. a pilot study of the Southeastern Cancer Study Group Cancer Clinical Trials 3(4): 293-296